Investigating the effectiveness and mechanism of Xinbao pill in micro vascular angina treatment

Coronary micro vascular dysfunction is attracting increasing attention, yet effective treatments remain inadequate. This study analysed the clinical efficacy and potential mechanisms of Xinbao pill in patients with microvascular angina (MVA). 200 MVA patients admitted from January 2020 to June 2021 were randomly divided into the control group (n = 100) and an observation group (n=100). Both groups received standard treatment, the observation group added Xinbao pill treatment. The clinical outcomes and angina symptoms were evaluated in both groups. The total clinical effective rate, angina symptom SAQ score, NO level, CFR and treadmill exercise test total exercise time of the two groups were considerably increased after treatment and the observation group was remarkably higher than the control group (P<0.05). Meanwhile, the number of exertional angina pectoris attacks, ET-1 levels, serum inflammatory factor levels and the maximum depression degree of ST segment were considerably lower after treatment, and the observation group was remarkably lower than the control group (P<0.05). The use of Xinbao pills in the treatment of MVA is significantly effective in reducing the symptoms of angina pectoris, reducing the levels of inflammatory factors and ET-1, which can further improve the efficacy and safety.